Results 201 to 210 of about 62,912 (312)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension [PDF]

, 2023
Lihi Eder, Dafna D. Gladman, Philip J. Mease, Remy A. Pollock, Rayana Leal Luna, Sibel Zehra Aydın, Alexis Ogdie, Ari Polachek, David Gruben, Mary Jane Cadatal, C. Kinch, Vibeke Strand   +11 more
openalex   +1 more source

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report

Respirology Case Reports, Volume 14, Issue 2, February 2026.
We present a case of ILD preceding RA onset. The disease activity of arthritis and ILD was controlled, and ILD was stabilised for 4 years with the JAK1 selective inhibitor, filgotinib. ABSTRACT We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA).
Takeo Sato, Shoko Nakazawa, Shotaro Yamamoto, Katsuya Nagatani, Kojiro Sato   +4 more
wiley   +1 more source

Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome [PDF]

, 2020
Wenhui Xie, Hong Huang, Zhuoli Zhang
openalex   +1 more source

Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Bowel urgency (BU) is reported by over 80% of patients with ulcerative colitis (UC) and 60% of those with Crohn's disease (CD). However, the impact of advanced therapies on BU has not been consistently evaluated. Objectives To assess the effect of advanced therapies on BU improvement in patients with UC and CD.
Ferdinando D'Amico, Olga Maria Nardone, Alessandro Bruno, Mariangela Allocca, Alessandra Zilli, Federica Furfaro, Tommaso Lorenzo Parigi, Virginia Solitano, Federica Ungaro, Ilaria Faggiani, Alessia La Mantia, Giulio Calabrese, Gionata Fiorino, Vipul Jairath, Laurent Peyrin‐Biroulet, Luca Massimino, Fabiana Castiglione, Silvio Danese   +17 more
wiley   +1 more source

P369. Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis [PDF]

, 2016

openalex   +1 more source

Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
M. R. Naber, A.E van der Meulen, P. W. Voorneveld, S. H. C. Veltkamp, A.A. van Bodegraven, A. Bodelier, Z. Mujagic, M. Pierik, L. M. M. Verleye, M. Duijvestein, D. G. Bouwknegt, M. C. Visschedijk, N. Srivastava, R. L. West, B. Oldenburg, M. Löwenberg, F.D.M. van Schaik, On behalf of the Dutch ICC Registry   +17 more
wiley   +1 more source

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source

Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors

International Journal of Dermatology, Volume 65, Issue 2, Page 230-237, February 2026.
Inmunization and Screening Protocol for the Safe Initiation of JAK Inhibitors. ABSTRACT Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine ...
Mariano Ara‐Martín, Carolina Moreno, Ricardo Ruiz‐Villaverde, Esther Serra‐Baldrich, Irene Hernández‐Martín, Maria del Pilar Fortes   +5 more
wiley   +1 more source

Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis. [PDF]

Int J Clin Pharmacol Ther
Tsuchiwata S, Suzuki A, Wang Q, Kanik K, Fallon L, Menon S.   +5 more
europepmc   +1 more source

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

, 2021
Manasi Agrawal, Erica J. Brenner, Xian Zhang, Irene Modesto, John Woolcott, Ryan C. Ungaro, Jean‐Frédéric Colombel, Michael D. Kappelman   +7 more
openalex   +1 more source